Ligand Pharmaceuticals/$LGND
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ticker
$LGND
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
68
ISIN
US53220K5048
Website
LGND Metrics
BasicAdvanced
$2.7B
-
-$7.11
0.76
-
Price and volume
Market cap
$2.7B
Beta
0.76
52-week high
$137.84
52-week low
$90.29
Average daily volume
152K
Financial strength
Current ratio
5.271
Quick ratio
4.29
Long term debt to equity
0.448
Total debt to equity
0.559
Interest coverage (TTM)
-4.42%
Profitability
EBITDA (TTM)
18.658
Gross margin (TTM)
56.70%
Net profit margin (TTM)
-73.07%
Operating margin (TTM)
-9.16%
Effective tax rate (TTM)
17.68%
Revenue per employee (TTM)
$2,670,000
Management effectiveness
Return on assets (TTM)
-1.14%
Return on equity (TTM)
-16.56%
Valuation
Price to revenue (TTM)
14.141
Price to book
3.33
Price to tangible book (TTM)
6.06
Price to free cash flow (TTM)
50.38
Free cash flow yield (TTM)
1.98%
Free cash flow per share (TTM)
273.07%
Growth
Revenue change (TTM)
53.40%
Earnings per share change (TTM)
-231.49%
3-year revenue growth (CAGR)
-6.62%
10-year revenue growth (CAGR)
11.13%
3-year earnings per share growth (CAGR)
72.68%
10-year earnings per share growth (CAGR)
30.33%
What the Analysts think about LGND
Analyst ratings (Buy, Hold, Sell) for Ligand Pharmaceuticals stock.
Bulls say / Bears say
Ligand Pharmaceuticals' partner, Travere Therapeutics, received full FDA approval for FILSPARI® (sparsentan), a non-immunosuppressive treatment for IgA nephropathy, entitling Ligand to a 9% royalty on worldwide net sales. (stocktitan.net)
The company's strategic merger of its subsidiary Pelthos Therapeutics with Channel Therapeutics, accompanied by a $50.1 million private placement, is expected to enhance its commercial portfolio and pipeline. (stockanalysis.com)
Analysts have a 'Strong Buy' consensus on LGND stock, with an average 12-month price target of $144.71, indicating a potential upside of approximately 27.72% from the current price. (stockanalysis.com)
Ligand Pharmaceuticals reported a fourth-quarter loss of $31.1 million, translating to a loss per share of $1.64, raising concerns about its profitability. (webull.com)
State Street reduced its stake in Ligand Pharmaceuticals by 26.76%, decreasing its ownership from 5.31% to 3.85%, which may signal waning institutional confidence. (nasdaq.com)
The company's forward P/E ratio stands at 18.94, which may be considered high relative to its earnings, potentially indicating overvaluation. (cnbc.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
LGND Financial Performance
Revenues and expenses
LGND Earnings Performance
Company profitability
LGND News
AllArticlesVideos
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
GlobeNewsWire·1 week ago
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
GlobeNewsWire·2 weeks ago
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ligand Pharmaceuticals stock?
Ligand Pharmaceuticals (LGND) has a market cap of $2.7B as of July 18, 2025.
What is the P/E ratio for Ligand Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ligand Pharmaceuticals (LGND) stock is 0 as of July 18, 2025.
Does Ligand Pharmaceuticals stock pay dividends?
No, Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Ligand Pharmaceuticals dividend payment date?
Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ligand Pharmaceuticals?
Ligand Pharmaceuticals (LGND) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.